Stereotaxis Announces First GenesisX Robotic System Order
ST. LOUIS, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it has received the first order for its latest generation robotic system, GenesisX™.
'We are thrilled to announce the first firm order for GenesisX from a pioneering European hospital,' said David Fischel, Stereotaxis Chairman and CEO. 'Establishing the first GenesisX robotic lab is a critical milestone for us as we advance towards full commercial launch. We look forward to demonstrating the performance and reliability of GenesisX in the demanding clinical environment. GenesisX promises to transform the accessibility of Robotic Magnetic Navigation and is central to our mission of driving broad robotic adoption throughout endovascular surgery.'
GenesisX is the latest advance in endovascular surgical robotics, building upon the established benefits of Robotic Magnetic Navigation while significantly enhancing the accessibility of the technology for healthcare providers. GenesisX utilizes smaller magnets and incorporates magnetic shielding into its structure in place of the shielding otherwise installed in the walls of the operating room. It requires no structural anchoring through the floor and operates using standard 120/230V power outlets. A single fiber is routed from each robot to the system cabinet, which is 80% smaller than previous cabinets and can fit under a table in the operating room. GenesisX is smaller and lighter than any previous generation system, while maintaining the highest standards in speed, responsiveness, and efficient workflow.
GenesisX obtained CE Mark in Europe in 2024 and has been submitted to the FDA for 510(k) clearance in the United States. During 2025, Stereotaxis plans to gain regulatory approvals in Europe and the US for a portfolio of compatible EP and vascular catheters, demonstrate real-world use of GenesisX, enhance compatibility of GenesisX with various x-rays, and prepare supply chain, manufacturing, installation and commercial processes for a full launch.
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com
This press release includes statements that may constitute 'forward-looking' statements, usually containing the words 'believe', 'estimate', 'project', 'expect' or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, statements relating to our recent acquisition of APT, including any benefits expected from the acquisition, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.
David L. Fischel
Kimberly Peery
Chief Financial Officer
314-678-6100
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
NATO chief Rutte calls for 400% increase in the alliance's air and missile defense
LONDON (AP) — NATO members need to increase their air and missile defenses by 400% to counter the threat from Russia, the head of the military alliance plans to say on Monday. Secretary-General Mark Rutte will say during a visit to London that NATO must take a 'quantum leap in our collective defense' to face growing instability and threats, according to extracts released by NATO before Rutte's speech. Rutte is due to meet U.K. Prime Minister Keir Starmer at 10 Downing St. ahead of a NATO summit in the Netherlands where the 32-nation alliance is likely to commit to a big hike in military spending. Like other NATO members, the U.K. has been reassessing its defense spending since Russia's full-scale invasion of Ukraine in February 2022. Starmer has pledged to increase British defense spending to 2.5% of gross domestic product by 2027 and to 3% by 2034. Rutte has proposed a target of 3.5% of economic output on military spending and another 1.5% on 'defense-related expenditure' such as roads, bridges, airfields and sea ports. He said last week he is confident the alliance will agree to the target at its summit in The Hague on June 24-25. At the moment, 22 of the 32 member countries meet or exceed NATO's current 2% target. The new target would meet a demand by President Donald Trump that member states spend 5% of gross domestic product on defense. Trump has long questioned the value of NATO and complained that the U.S. provides security to European countries that don't contribute enough. Rutte plans to say in a speech at the Chatham House think tank in London that NATO needs thousands more armored vehicles and millions more artillery shells, as well as a 400% increase in air and missile defense. 'We see in Ukraine how Russia delivers terror from above, so we will strengthen the shield that protects our skies,' he plans to say. 'Wishful thinking will not keep us safe. We cannot dream away the danger. Hope is not a strategy. So NATO has to become a stronger, fairer and more lethal alliance.' European NATO members, led by the U.K. and France, have scrambled to coordinate their defense posture as Trump transforms American foreign policy, seemingly sidelining Europe as he looks to end the war in Ukraine. Last week the U.K. government said it would build new nuclear-powered attack submarines, prepare its army to fight a war in Europe and become 'a battle-ready, armor-clad nation.' The plans represent the most sweeping changes to British defenses since the collapse of the Soviet Union more than three decades ago.
Yahoo
29 minutes ago
- Yahoo
Iran says to submit own nuclear proposal to US soon
Iran said Monday it will soon present a counter-proposal on a nuclear deal with the United States, after it had described Washington's offer as containing "ambiguities". Tehran and Washington have held five rounds of talks since April to thrash out a new nuclear accord to replace the deal with major powers that US President Donald Trump abandoned during his first term in 2018. The longtime foes have been locked in a diplomatic standoff over Iran's uranium enrichment, with Tehran defending it as a "non-negotiable" right and Washington describing it as a "red line". On May 31, after the fifth round talks, Iran said it had received "elements" of a US proposal, with Foreign Minister Abbas Araghchi saying later the text contained "ambiguities". Foreign Ministry spokesman Esmaeil Baqaei criticised the US proposal as "lacking elements" reflective of the previous rounds of negotiations, without providing further details. "We will soon submit our own proposed plan to the other side through (mediator) Oman once it is finalised," Baqaei told a weekly press briefing. "It is a proposal that is reasonable, logical, and balanced, and we strongly recommend that the American side value this opportunity." Iran's parliament speaker has said the US proposal failed to include the lifting of sanctions -- a key demand for Tehran, which has been reeling under their weight for years. - 'Strategic mistake' - Trump, who has revived his "maximum pressure" campaign of sanctions on Iran since taking office in January, has repeatedly said it will not be allowed any uranium enrichment under a potential deal. On Wednesday, Iran's supreme leader Ayatollah Ali Khamenei said the US offer was "100 percent against" notions of independence and self-reliance. He insisted that uranium enrichment was "key" to Iran's nuclear programme and that the US "cannot have a say" on the issue. Iran currently enriches uranium to 60 percent, far above the 3.67-percent limit set in the 2015 deal and close though still short of the 90 percent needed for a nuclear warhead. Western countries, including the United States, have long accused Iran of seeking to acquire atomic weapons, while Iran insists its nuclear programme is for peaceful purposes The United Nations nuclear watchdog will convene a Board of Governors meeting from June 9-13 in Vienna to discuss Iran's nuclear activities. The meeting comes after the International Atomic Energy Agency released a report criticising "less than satisfactory" cooperation from Tehran, particularly in explaining past cases of nuclear material found at undeclared sites. Iran has criticised the IAEA report as unbalanced, saying it relied on "forged documents" provided by its arch foe Israel. Britain, France and Germany, the three European countries who were party to the 2015 deal, are currently weighing whether to trigger the sanctions "snapback" mechanism in the accord. The mechanism would reinstate UN sanctions in response to Iranian non-compliance -- an option that expires in October. On Friday, Araghchi warned European powers against backing a draft resolution at the IAEA accusing Tehran of non-compliance, calling it a "strategic mistake". On Monday, Baqaei said Iran has "prepared and formulated a series of steps and measures" if the resolution passed. "Without a doubt, the response to confrontation will not be more cooperation," he added. rkh-mz/ysm
Yahoo
31 minutes ago
- Yahoo
Nutraceutical Excipients Global Strategic Business Report 2025-2030: Technological Innovations in Multi-Functional Excipients Propel Growth, Increasing Preference for Clean-Label and Natural Ingredients
The global Nutraceutical Excipients market is expected to grow from USD 5 billion in 2024 to USD 7.2 billion by 2030, at a CAGR of 6.2%. Key trends driving this market include a shift towards clean-label, organic excipients and technological advances like nanotechnology that enhance ingredient bioavailability. This report offers comprehensive insights into market trends, regional growth projections, and strategic opportunities, identifying major players such as ABF Ingredients and Cargill. Explore detailed regional analyses and future market insights to inform strategic decisions. Nutraceutical Excipients Market Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "Nutraceutical Excipients - Global Strategic Business Report" report has been added to global market for Nutraceutical Excipients was valued at US$5.0 Billion in 2024 and is projected to reach US$7.2 Billion by 2030, growing at a CAGR of 6.2% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. Nutraceutical excipients are inactive ingredients used in the production of nutraceutical products such as dietary supplements, functional foods, and fortified beverages. These excipients serve a crucial role by aiding in the stabilization, preservation, and delivery of active ingredients like vitamins, minerals, and bioactive compounds. Growth in the Nutraceutical Excipients Market Is Driven by Several FactorsGrowth in the nutraceutical excipients market is driven by several factors, including innovations in excipient technology, evolving consumer preferences, and increasing regulatory scrutiny. Advances in excipient formulations, such as the development of multifunctional and bioenhancing excipients, are expanding the range of nutraceutical products available to consumers. The growing popularity of clean-label and organic products is also fueling demand for natural excipients that meet consumer expectations for purity and safety. Additionally, the rise in chronic health conditions and aging populations is increasing the need for functional and targeted nutraceuticals, further driving demand for excipients that improve the bioavailability and stability of active ingredients. Regulatory requirements for product safety and quality are pushing manufacturers to innovate, ensuring excipients meet the highest standards for efficacy and safety. How Are Innovations in Nutraceutical Excipients Shaping the Market?Technological advancements in excipient development are driving significant changes in the nutraceutical market. The demand for excipients that are organic, non-GMO, and free from allergens is on the rise, reflecting consumer preferences for clean-label products. New innovations in multifunctional excipients, which can perform multiple roles such as improving both bioavailability and stability, are gaining traction. Additionally, advancements in nanotechnology are enabling the development of excipients that enhance the solubility and absorption of poorly soluble nutraceutical ingredients. These innovations are leading to the production of more effective, faster-acting, and longer-lasting nutraceutical products, appealing to consumers who prioritize both efficacy and natural Are Consumer Preferences and Regulatory Trends Impacting Demand for Nutraceutical Excipients?The growing focus on health and wellness has spurred consumer demand for nutraceutical products that are safe, effective, and free from artificial additives. This shift is influencing the nutraceutical excipients market, as manufacturers are increasingly opting for natural, organic, and clean-label excipients that align with consumer values. Regulatory bodies are also playing a key role by setting stringent guidelines for excipient safety and quality, particularly in regions like North America and Europe. As a result, excipient manufacturers are investing in research and development to create products that comply with these regulations while offering superior functionality. Moreover, the rise of personalized nutrition is driving demand for excipients that enable the production of customized nutraceutical solutions, expanding the market's Scope Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as ABF Ingredients, Cargill, Inc., Dow, Inc., DuPont de Nemours, Inc., EGGLE Wasserburg Verwaltungs GmbH and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Key Insights: Market Growth: Understand the significant growth trajectory of the Binders segment, which is expected to reach US$2.4 Billion by 2030 with a CAGR of a 7.6%. The Fillers & Diluents segment is also set to grow at 5.5% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $1.3 Billion in 2024, and China, forecasted to grow at an impressive 9.5% CAGR to reach $1.7 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Segments: Functionality (Binders, Fillers & Diluents, Coating Agents, Lubricants, Disintegrants, Flavoring Agents) Form (Dry, Liquid) Tariff Impact Analysis: Key Insights for 2025What's Included in This Edition: Tariff-adjusted market forecasts by region and segment Analysis of cost and supply chain implications by sourcing and trade exposure Strategic insights into geographic shifts Buyers receive a free July 2025 update with: Finalized tariff impacts and new trade agreement effects Updated projections reflecting global sourcing and cost shifts Expanded country-specific coverage across the industry Key Attributes: Report Attribute Details No. of Pages 308 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $5 Billion Forecasted Market Value (USD) by 2030 $7.2 Billion Compound Annual Growth Rate 6.2% Regions Covered Global Key Topics Covered: MARKET OVERVIEW Influencer Market Insights Tariff Impact on Global Supply Chain Patterns Global Economic Update Nutraceutical Excipients - Global Key Competitors Percentage Market Share in 2024 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E) MARKET TRENDS & DRIVERS Rising Consumer Demand for Functional Foods and Dietary Supplements Drives Growth in Nutraceutical Excipients Market Technological Advancements in Drug Delivery Systems Propel the Adoption of Innovative Nutraceutical Excipients Increasing Preference for Clean-Label and Natural Ingredients Expands the Market for Organic Nutraceutical Excipients Growing Focus on Enhanced Bioavailability and Solubility Strengthens Demand for Advanced Excipient Formulations Rising Awareness of Preventative Healthcare and Wellness Fuels Growth in Nutraceutical Supplements, Driving Excipient Demand Technological Innovations in Multi-Functional Excipients Propel Growth in Nutraceutical Manufacturing Efficiency Increased Regulatory Scrutiny on Ingredient Safety and Quality Standards Spurs Demand for Compliant Excipients Growing Use of Probiotics and Prebiotics Expands Opportunities for Specialized Nutraceutical Excipients Consumer Trends Toward Sugar-Free and Low-Calorie Supplements Accelerate Demand for Sweetening and Flavoring Excipients Expansion of Sports Nutrition and Weight Management Products Throws the Spotlight on Performance-Enhancing Excipients Rising Popularity of Plant-Based and Vegan Nutraceuticals Strengthens the Business Case for Non-Animal Derived Excipients Growth in Elderly Population and Demand for Age-Related Supplements Propel Market Adoption of Digestive-Friendly Excipients FOCUS ON SELECT PLAYERS ABF Ingredients Cargill, Inc. Dow, Inc. DuPont de Nemours, Inc. EGGLE Wasserburg Verwaltungs GmbH Hilmar Ingredients IMCD Group BV Ingredion, Inc. Innophos Holdings, Inc. Jrs Pharma GmbH Co. KG Kerry Group plc Roquette Freres S.A. Sensient Pharmaceutical For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Nutraceutical Excipients Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
